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Abstract
Background: Patient reported outcomes and costs of illness are useful to capture some of the multiple effects of a disease
and its treatments. Our aim was to assess quality of life (QoL) and costs of Parkinson’s disease (PD) in Hungary, and to
analyze their associations.
Methods: A cross-sectional questionnaire survey was conducted in one neurology university clinic. Clinical characteristics,
PD related resource utilizations and productivity loss in the past 12 months were recorded; the Hoehn&Yahr (HY) scale,
PDQ-39 and EQ-5D questionnaires were applied. Cost calculation was performed from the societal perspective.
Results: 110 patients (34.5% female) were involved with mean age of 63.3 (SD = 11.3) and disease duration of 8.2 (SD = 5.8)
years. PDQ-39 summary score was 48.1 (SD = 13.4). The average EQ-5D score was 0.59 (SD = 0.28), and was significantly
lower than the population norm in age-groups 45–74. The correlation was significant between EQ-5D and PDQ-39 (20.47,
p = 0.000), the HY scale and EQ-5D (20.3416, p = 0.0008) and PDQ-39 (0.3419, p = 0.0006) scores. The total mean cost was
J6030.2 (SD = 6163.0)/patient/year (direct medical 35.7%, direct non-medical 29.4%, indirect cost 34.9%). A one year
increase in disease duration and 0.1 decrease of the EQ-5D utility score increase the yearly costs by 8 to 10%, and 7.8%,
respectively. The effect of the PDQ-39 score on total cost was not significant.
Conclusions: Disease severity and public health importance of PD are clearly demonstrated by the magnitude of QoL loss.
PD-related costs are substantial, but are much lower in Hungary than in Western European countries. Disease duration and
EQ-5D score are significant proxy of costs.
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Introduction
Parkinson’s disease (PD) is one of the most common neurode-
generative disorders [1]. In Hungary, about 20 000 people live
with PD [2]. Over the past two years, cost of illness studies from
various European countries have been reported that PD related
costs substantially vary from country to country [3–7]. In Central
Eastern Europe detailed cost of illness analysis in PD was
published only from the Czech Republic and Russia [6–7],
therefore, estimation of the disease burden from PD in Europe is
very limited. Local data and evidence in the country-specific
context are needed for health economic evaluations that have
become increasingly important in PD with the spread of advanced
device-aided therapies.
Our aim was to provide evidence on health-related quality of
life (HRQL) of patients with PD and cost of illness in Hungary,
and to analyze the relationship between diverse health measures
and costs.
Methods
Patients
Patients with established diagnosis of PD attending routine care
between November 2008 and March 2010 at the Department of
Neurology, Semmelweis University, in Budapest were invited to
participate in a cross-sectional survey. Ethical approval (reference
number: 10796-0/2010-1018EKU) was obtained from the Hun-
garian Medical Research Council. Patients signed informed
consent form. All of the patients had the cognitive ability to
consent according to the findings in the neurological examination;
therefore, there was no surrogate consent procedure.
Questionnaire
Demographic data, employment status, main clinical charac-
teristics, PD related medication, use of health care services in the
past 12 months, transportation utilizations to attend medical care,
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and help from others for everyday activities (informal care) were all
surveyed.
Neurologists categorized patients by disease severity using the
Hoehn&Yahr scale (HY) [8]. Patients’ general health status was
measured with the EQ-5D-3L (hereinafter EQ-5D) questionnaire
and a Visual Analogue Scale (EQ VAS) [9]. Due to lack of
national tariffs the UK algorithm was used to calculate the EQ-5D
utility score. The health-related quality of life was assessed by the
PDQ-39 [10].
Costs
Hungarian official costs, tariffs and reimbursement lists of 2009
and the utilization data reported by patients were used for cost
calculation. The cost of consultation was calculated by multiplying
the number of visits by the estimated unit prices (GP: J5.5/visit,
out-patient specialist: J6.7/visit). The costs of hospitalizations
were based on Disease Related Groups reimbursement lists
(J825.54 per occasion). Diagnostic procedures were evaluated
on official outpatient prices (e.g. skull MRI: J56.6/case). Drug
costs were calculated based on official prices of pharmaceuticals
and the doses reported by the patient. We did not involve drugs
treating non-motor symptoms to the analysis similarly to other cost
estimating studies [6–7]. Non-reimbursed medical services’ costs
were based upon patients’ answers. The cost of ambulance was
calculated by the estimated costs/km (J3.7/km), multiplied by the
distance of the patient’s home to the clinic and the number of
utilizations.
Transportation cost of patient and the accompanying person
was calculated considering the way of transportation used and the
distance between patients’ residence and neurology care. Weekly
cost of informal care was calculated using the average hourly net
wage in Hungary (J2.8/hour) multiplied by the number of hours/
week, and it was projected to a 12 months period but capped for
the yearly net wage.
The costs of sick leave, part time job and full disability due to
PD were calculated using human capital approach method.
Average gross income (J957/month in 2009) including net wage,
personal income tax, pension contribution, health insurance
contributions, employers’ contribution was multiplied with the
time off work. Conversion (280.6 Hungarian Forints =J1) was
applied.
Statistical analysis
We used Student t-test to compare the EQ-5D scores of PD
patients to the general Hungarian population by age groups, the
significance level of 5% was applied. We also calculated pair-wise
correlation between EQ-5D scores, EQ VAS, PDQ-39 indices and
HY categories. We used one-way ANOVA test to examine,
whether the costs significantly differ by HY categories. We
examined the relation between health-related indices, disease
severity and costs using multivariate linear regression analysis. We
used the logarithm of the cost as dependent variable; age and
gender of the patients, HRQL indices (EQ-5D, EQ VAS, PDQ-
39) and disease severity (HY category) as independent variables.
We built four models separately for the four independent
variables. Stata 11 software was used for the analysis.
Results
Main characteristics and health status of the sample
Main characteristics of the patient sample (N = 110) are
summarized in Table 1 and Table S1.
EQ-5D
The EQ-5D and EQ VAS scores were mean 0.59 (SD = 0.28)
and 59.3 (SD = 17.9), respectively (Figure 1A). Patients with PD
had a significantly lower average EQ-5D score in age-groups 45–
54 (N = 14), 55–64 (N = 37), 65–74 (N = 34) than the general
population (p,0.05) [11]. The difference was not significant in
age-group 75–84 (N = 16). The number of patients in age groups
25–34, 35–44 and $85 was not sufficient for the analysis (N = 1; 5
and 3, respectively). Mobility was the most problematic health
area for the PD patients (Figure 2).
PDQ-39
The average total score of PDQ-39 was 48.1 (median: 47.8;
SD = 13.4; min-max: 8.3–79.4) (Figure 1B) and the mean scores
by health dimensions were as follows: mobility: 50.0 (median: 47.5;
SD = 21.4; min-max: 0–100), activities of daily living: 51.3 (median
50; SD = 22.1; min-max: 0–100), emotional well-being: 52.8
(median: 47.9; SD = 20.6; min-max: 0–100), stigma: 50.8 (median:
43.8; SD = 24.4; min-max: 0–100), social support: 32.5 (median:
25; SD = 15.0; min-max: 0–100), cognitions: 45.3 (median: 43.8;
SD = 19.3; min-max: 12.5–100), communication: 43.8 (median:
47.1; SD = 18.8; min-max: 8.3–100), bodily discomfort: 58.2
(median: 58.3; SD = 21.9; min-max: 0–100).
Health status by disease severity and correlation of HRQL
scores
Results by HY categories are presented on Figure 1A,B. We
found significant differences in EQ-5D, EQ VAS and PDQ-39
scores between the HY category I and II (p,0.01). However, the
differences were not significant neither between the HY group II
and III, nor between III and IV. We found a significant moderate
correlation between the EQ-5D and EQ VAS scores (0.49;
p = 0.000) as well as between EQ-5D and PDQ-39 scores (20.47;
p = 0.000). Significant but weaker correlation was found between
EQ VAS and PDQ-39 (20.31; p = 0.002), as well as between the
HY scale and the EQ-5D (20.3416, p = 0.0008), the EQ VAS (2
0.3683, p = 0.0004) and the PDQ-39 score (0.3419, p = 0.0006).
The correlation between disease duration and EQ-5D score was
significant but moderate (20.32, p = 0.0015), and significant but
week between disease duration and PDQ-39 score (0.25,
p = 0.0117).
We found a moderate significant correlation between disease
duration and direct medical costs (0.40, p = 0.000) as well as low
but significant correlation between disease duration and total costs
(0.25, p = 0.0095). The correlation was not significant between
disease duration and direct non-medical costs, nor it was between
disease duration and indirect costs (p.0.05).
Health care utilization and costs
One patient did not provide data on healthcare utilization
therefore cost of illness calculation was performed considering a
sample of 109 patients. At the time of the survey 94 (86.2%)
patients were on medication due to PD. None of the patients had
surgery in the last 12 months.
The average yearly total cost per patient was J6030.2
(SD = 6163.0), distribution between direct medical, direct non-
medical and indirect cost was 35.7%, 29.4% and 34.9%,
respectively (Table 2). Drugs contributed to 75% of the direct
medical costs (Table 2 and Table S2), and drug cost increased
with disease severity (Figure 1C).
The annual average cost per patient by HY categories were I:
J1543.3 (SD = 1451.4), II: J5620.9 (SD = 7478.2), III: J8325.5
(SD = 5811.4) and IV: J7462.3 (SD = 6302.2), respectively, and
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none of the patients were in HY-V stage (Figure 1D). According to
the results of the ANOVA test, total cost was significantly
influenced by HY stages (F3,97 = 6.22, p = 0.0007). Post-estima-
tions revealed significant difference between the cost in HY-I and
II stages (F1,97 = 5.69 p = 0.0190), but not in HY-II and III
(F1,97 = 3.59, p = 0.0610), and in HY-III and IV stages
(F1,97 = 0.19, p = 0.6665).
We found significant differences between HY stages in direct
medical costs (F3,97 = 4.86, p = 0.0034), namely between HY stages
II and III (F1,97 = 7.50, p = 0.0074), as well as in indirect costs
(F3,97 = 3.24, p = 0.0254), namely between stages II and III
Table 1. Characteristics of patients with Parkinson’s disease.
Variables Mean (SD)
Age, year (N = 110) 63.3 (11.3)
Disease duration, year (N = 108) 8.2 (5.8)
Weight, kg (N = 109) 74.1 (13.1)
Height, cm (N = 108) 169.7 (8.9)
Body Mass Index (N = 108) 25.6 (3.7)
Number of patients (%)
Gender
females 38 (34.5)
males 70 (63.6)
missing data 2 (1.8)
Hoehn&Yahr scale
I 20 (18.2%)
II 30 (27.3%)
III 41 (37.3%)
IV 11 (10.0%)
V 0 (0.0%)
Missing data 8 (7.3%)
For details see also Table S1.
doi:10.1371/journal.pone.0107704.t001
Figure 1. Quality of life, costs of medication, cost components in the Hoehn&Yahr categories. A: EQ-5D and VAS scores B: PDQ-39 index
scores C: Costs of medication therapy related to Parkinson’s disease D: Distribution of cost components. Vertical lines indicate standard deviations.
doi:10.1371/journal.pone.0107704.g001
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(F1,97 = 2.93, p = 0.0900). At the same time, we did not find
significant differences between HY stages in direct nonmedical
costs (F3,97 = 1.90, p = 0.1348).
Regression analysis
Results are presented in Table 3. The first three models built for
the logarithm of total costs with different independent variables for
the EQ-5D, EQ VAS and PDQ-39 separately, are significant at
5% levels (p,0.05). We found that one year progression of the
disease increases the yearly costs by 8.0%, 9.9% and 9.3%,
depending on the model specification. A 0.1 point decrease of the
EQ-5D score results in 7.8% increase of the cost while 1 point
decrease on the EQ VAS scale causes 2.3% cost increase. The
relationship between the PDQ-39 and total cost was not
significant.
In the fourth model, when we include the severity categories
(HY) as dummy variables controlled for age, gender and disease
duration, we find that compared to the HY III group, the costs of
the HY I and HY II groups are significantly lower, by 91.3% and
30.7%, respectively. The difference between average annual cost
per patient between groups HY IV and III was not significant. In
this model age and gender are also significant, while disease
duration is not.
Discussion
In this study, we have assessed HRQL and costs of illness of PD
in a cross-sectional questionnaire survey involving 110 patients
and compared different health measures and costs.
The PDQ-39 questionnaire revealed the highest deterioration in
the bodily discomfort and emotional well-being areas, however
similar impairment was detected in mobility, activities of daily
living and stigma as well. The average PDQ-39 summary index
score in Hungary (48.1, SD = 13.4) was comparable to the findings
in Spain [12] (48.8, SD = 27.8) and Croatia [13] (median SI: 47,
interquartile range: 32–62) but was higher than in Germany [14]
(29.4, SD = 17.5), France [15] (36.5, SD = 14.2), Norway [16]
(18.7, SD = 12.0) and Poland [17] (32.17, SD = 16.82) at a similar
mean age and disease duration. It thus seems that disease-specific
HRQL of PD patients are worse in Hungary than in economically
more developed European countries. It can be inferred that the
differences originate from various factors, including social support,
co-morbidities and access to chronic care [18].
The EQ-5D score was lower in PD than in the age matched
general population in Hungary; the most affected health
dimensions were mobility and the performance of usual activities.
In a study across 10 countries, Martinez-Martin et al. [19]
reported similar average EQ-5D scores at a similar mean age
(64.5, SD = 9.9) and disease duration (8.1, SD = 5.7).
We found significant moderate correlation between the PDQ-
39 summary score and the EQ-5D utility index, but the
correlation with the EQ VAS was weaker, which is in line with
international findings [20]. The correlation was significant, but
moderate between HY stages and the three health indices. Our
results confirm the limited capacity of HY medical categorical
scale to consider important HRQL aspects, thus HY based cost-
effectiveness models using EQ-5D utility values should be
evaluated in appropriate sensitivity analyses [21].
The cost of illness of PD was mean J6030/patient/year in
Hungary (Table 2). Among drugs, the combination of levodopa,
decarboxylase inhibitor and COMT-inhibitor (Stalevo) was of the
highest cost, followed by dopamine agonists. Subcutan apomorfin
pump is not yet available in Hungary, and patients with deep brain
stimulation or jejunal Levodopa/carbidopa infusion were not in
the sample, so their contributions to PD-related costs in Hungary
are still lacking.
Informal care provided by family members, or volunteers
occurred in 43% of the patients, which contributed to 43% of the
Figure 2. EQ-5D results in Parkinson’s disease and the general population in Hungary. Rate of PD patients reporting different levels of
problem in the EQ-5D scale, in comparison with the general population in Hungary [11]. PD: Patients with PD, age mean 63.3 (SD: 11.3) years, N = 110;
C: control, general population, age-group 60–69 yrs, N = 721.
doi:10.1371/journal.pone.0107704.g002
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direct costs (Table 2). It seems that in Hungary, PD related
disability mainly burdens the patients’ families, and not the health
and social care system. Despite the relatively high average age of
the sample unemployment affected about one quarter of the
patients, thus indirect costs were the highest cost category (35%). It
is worthy to note that the standard deviation (SD) of costs was
quite large (mean 6030.2, SD = 6163.0 euros/patient/year).
Although it was observed in all the three cost categories, the
largest SD was found for indirect cost category. For those patients
who were working or were retired the productivity lost was 0,
while for those who were disabled due to their PD we calculated
with a one year gross wage loss which was 11,5 thousand euros in
Hungary. This partly explains the high standard deviation of
annual cost.
One major conclusion of a comparative study in six countries
was that total costs from a societal perspective were lower in
Eastern, than in Western European countries. Our results seem to
strengthen this observation, although direct comparison is
Table 2. Resource utilization and costs of patients with Parkinson’s disease in Hungary.
Resource utilisation Average yearly cost, EUR/patient/year
Rate of patients
with at least one
occasion (%)
Mean of the quantity used in
the past 12 months (n=109)
Cost per patient
(total sample) Cost category (total sample)
Consultations (outpatient) - - 50.9 Direct medical cost: 2149.3 Euro/
patient/year (35.7%)
GP visit 68 (62.3%) 3.3 17.8
Specialist visit 100 (91.7%) 4.9 33.1
Hospital admission 37 (33.9%) 0.4 348.4
Diagnostics - - 42.5
CT scan 68 (62.4%) 0.4 8.0
MRI scan 54 (49.5%) 0.2 11.4
SPECT 17 (15.6%) 0.04 17.8
Laboratory tests 67 (601.5%) 0.8 0.7
X-ray 28 (25.7%) 0.1 0.5
Neuropsychology 41 (37.6%) 0.3 3.4
Doppler 21 (19.3%) 0.1 0.4
Tremor analysis 18 (16.5%) 0.1 0.2
Tests of autonomic functions 21 (19.3%) 0.2 0,1
Drugs (present users) - - 1614.3
MAO-B inhibitor 35 (32.1%) 179.1
Amantadine 29 (26.6%) 33.5
Anticholinergic drug 4 (3.7%) 3.9
Dopamin agonist 50 (45.9%) 484.7
Levodopa+decarboxylase inhibitor 59 (54.1%) 117.9
Levodopa+decarboxylase inhibitor+COMT
inhibitor
34 (31.2%) - 535.0
COMT-inhibitor 18 (16.5%) - 260.2
Other health care services - - 93.2
Not reimbursed services 19 (17.4%) - 57.2
Ambulance 8 (7.3%) 0.2 36.0
Non-medical cares - - 1774.6 Direct non-medical cost: 1774.6
EUR (29.4%)
Transportation 92 (84.45%) - 69.9
Informal care 47 (43.1%) 12.6 hours/week 1704.7
Productivity loss - - 2106.3 Indirect cost: 2106.3 EUR (34.9%)
Work disability pension* 19 (17.4%) NA 2002.7
Sick leave 5 (4.6%) 1.6 days/year 75.1
Part time job due to PD 1 (0.9%) NA 28.5
Total NA NA NA 6030.2 EUR
For cost of drugs see also Table S2.
(N=109; conversion J1=280.6 HUF);
* All of them are on disability pension due to their Parkinson’s disease.
doi:10.1371/journal.pone.0107704.t002
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hampered by methodological differences. The total costs of PD in
Hungary is expressed in purchasing power parity (PPP), 2009
euros was 10 144 J/patient/12 months (conversion PPP 2009
J1 = 166.8 HUF), which is closer to the Czech result (PPP 2008
J5510/patient/6 months), than to Austria, Germany, or Italy
(9820, 8610 and 8340 PPP 2008 J/patient/6 months, respective-
ly) [6]. In Hungary the medication costs were the main drivers of
direct costs. Similar to other European countries, and Russia [6],
the levodopa+decarboxylase inhibitor, or its combination with
COMT-inhibitor and dopamine-agonists, were most often pre-
scribed in Hungary, but MAO-B inhibitors were more frequently
used in our sample (Table 2 and Table S2), than most of these
countries except Portugal. Hospitalisation amounted to only 9%
(J348/patient/year) in Hungary, whilst it has been described as
one of the major cost factors in Western European countries,
comprising of 13%–42% of total direct costs. Informal care in PD
has been analyzed in five publications up to date, and its unit cost
varied between 2.36–7.99 USD (2010), and the average time from
8.90 to 17.25 hours/week [22]. It seems that informal care usage
in Hungary is in the upper range (12.6 hours/week), but its unit
cost is in the lower band (J2.8/hour).
Analysis by HY categories revealed a significant increase of total
cost between stages I and II, but not between II and III, and stages
III and IV in Hungary (Figure 1D). Drug costs (Figure 1C), and
direct medical costs increase with HY stages, but indirect costs
decrease between HY III–IV because all patients with the
exception of two disability pensioners were retired in the HY IV
subgroup. Thus, indirect costs were much lower in HY IV state, as
out of the 11 patients in the HY IV subgroup 9 were retired with
no productivity loss considered in their case. von Campenhausen
et al. found a similar trend in Portugal, however, in other countries
the increase of total costs was observed between HY III–IV [6].
Disease duration significantly correlated with direct medical costs
and total costs, but not with direct non-medical costs, and indirect
costs in our study.
In our study regression analysis confirmed significant relation-
ship between EQ-5D score and total costs. A 0.1 decrease of the
EQ-5D utility score increases the yearly costs by 7.8%, and one
year increase in disease duration raises it by 8–10% (Table 3).
Further studies, including more patients in worse HY stages, and
considering other clinical factors are required to confirm and
refine our observations.
The average yearly cost per patient in multiple sclerosis [23]
and schizophrenia [24] is about 1.7 and 2.3 higher compared to
PD in Hungary and costs of dementia [25] is also slightly higher. A
model-based estimate found similar trends in Europe; however,
they estimated a lower average cost for PD in Hungary on the
national level (PPP 2010 J5926) using extrapolations [26].
Limitations of our study have to be considered for the
interpretation of the results. The survey was performed in one
neurology university clinic, thus results cannot be generalized to
the whole PD patient population in Hungary. Patients in the most
severe health state (HY V category) were not involved. Regarding
informal care, we considered only caregivers’ time based on
patients’ answers and did not collect further data on caregivers’
employment status, productivity and quality of life loss. Nonethe-
less, there is a large methodological heterogeneity in the cost of
illness literature. We strongly agree with Dodel et al. [21] that
‘there is a need for a validated instrument that would provide more
reliable and transparent cost data for patients with PD to estimate
better the burden of the disease’. Taking into consideration the
significant rate of informal care in PD, this would be especially
important for the assessment and costing of help provided by
others for everyday life. Further studies, involving more represen-
tative samples might confirm or refine our results. Nevertheless
our study contributes with important observations to health
economic evaluations, and a better understanding of disease
burdens of PD across different countries.
Table 3. Results of the regression analysis models built for the EQ-5D, EQ VAS and PDQ-39 separately.
Variables Model 1 – EQ-5D Model 2 – EQ VAS Model 3 – PDQ-39 Model 4 – HY
{
ln (total cost) ln (total cost) ln (total cost) ln (total cost)
Age 20.021 (0.013) 20.027** (0.014) 20.0168 (0.013) 20.0338*** (0.012)
Male 20.325 (0.317) 20.356 (0.328) 20.274 (0.311) 20.466* (0.277)
Disease duration 0.076*** (0.028) 0.094*** (0.027) 0.0885*** (0.027) 0.0194 (0.032)
EQ-5D 21.530*** (0.561) - - -
EQ VAS - 20.023** (0.008) - -
PDQ-39 - - 0.0142 (0.011) -
HY I - - - 22.457*** (0.450)
HY II - - - 20.366* (0.189)
HY IV - - - 20.112 (0.115)
Constant 15.42*** (0.977) 16.14*** (1.162) 13.44*** (0.971) 16.60*** (0.899)
Observations 95 91 101 99
F 5.81 5.89 4.10 9.21
P 0.0003 0.0003 0.0041 0.000
R-squared 0.205 0.215 0.146 0.375
*p,0.1,
** p,0.05,
*** p,0.01;
{HY III was used as reference category in Model 4; t-statistics in parentheses.
doi:10.1371/journal.pone.0107704.t003
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